Research programme: cystic fibrosis transmembrane conductance regulator stimulants and inhibitors - University of California San Francisco/Vanda Pharmaceuticals

Drug Profile

Research programme: cystic fibrosis transmembrane conductance regulator stimulants and inhibitors - University of California San Francisco/Vanda Pharmaceuticals

Alternative Names: Cystic fibrosis transmembrane conductance regulator activators - University of California San Francisco/Vanda Pharmaceuticals; Cystic fibrosis transmembrane conductance regulator inhibitors - University of California San Francisco/Vanda Pharmaceuticals

Latest Information Update: 05 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of California at San Francisco
  • Class Eye disorder therapies; Laxatives; Urologics
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator inhibitors; Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Constipation; Diarrhoea; Dry eyes; Polycystic kidney disease

Most Recent Events

  • 30 Mar 2017 University of California San Francisco has issued and pending patents pending for cystic fibrosis transmembrane conductance regulator stimulants and inhibitors
  • 30 Mar 2017 Preclinical trials in Constipation in USA (unspecified route) before March 2017
  • 30 Mar 2017 Preclinical trials in Diarrhoea in USA (unspecified route) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top